Enter inventor name

Ranjit C Desai

This inventor holds 29 USPTO granted patents, primarily in Proteolytic Enzyme Inhibitors. Top assignees: Sterling Winthrop Inc., Sanofi, Sanofi Winthrop Inc.. Active years: 1992-1999.

USPTO Granted Patents = 29

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 11

Forward Citations = 475(Granted Patents)

Location History:

Colonie Township, Albany County, NY (US) (1992)
Harleysville, PA (US) (1996)
Corpus Christi, TX (US) (1996)
Towamencin Township, Montgomery County, PA (US) (1994 - 1998)
Kendall Park, NJ (US) (1998)
Colonie, NY (US) (1993 - 1999)
Towamencin Township, PA (US) (1995 - 1999)

Company Filing History:

20 out of 206

Sterling Winthrop Inc.

Years Active: 1992-1999

Loading Chart...

Areas of Expertise:

Proteolytic Enzyme Inhibitors

Saccharin Derivatives

Heterocyclic Carboxylates

Thiadiazolidin-3-One

Aryl Carboxylates

Phosphonates

Phosphinates

Dioxides

Fluorinated Compounds

Enzyme Inhibition

Phosphates

Substituted Compounds

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5874432 - Saccharin derivatives useful as proteolytic enzyme inhibitors and (1999-02-23),

2. 5856349 - 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic (1999-01-05),

3. 5773456 - Saccharin derivative proteolytic enzyme inhibitors (1998-06-30),

4. 5750550 - 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides (1998-05-12),

5. 5750546 - 2-(2, 3, 5, 6-tetrafluoro-4-pyridyl)-1, 2, 5-thiadiazolidin-3-one 1, (1998-05-12),

6. 5652254 - 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic (1997-07-29),

7. 5650422 - Saccharin derivatives useful as proteolytic enzyme inhibitors and (1997-07-22),

8. 5602154 - 2-(2,3,5,6-tetrafluoro-4-pyridyl)-1,2,5-thiadiazolidin-3-one (1997-02-11),

9. 5597841 - 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme (1997-01-28),

10. 5596012 - Saccharin derivatives useful as proteolytic enzyme inhibitors and (1997-01-21),

11. 5578623 - Saccharin derivative proteolytic enzyme inhibitors (1996-11-26),

12. 5563163 - 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic (1996-10-08),

13. 5556909 - Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one (1996-09-17),

14. 5541168 - Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one (1996-07-30),

15. 5512589 - 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme (1996-04-30),

Title: Ranjit C Desai: Innovator in Pharmaceutical Chemistry

Introduction

Ranjit C Desai, a distinguished inventor based in Colonie, NY, has made significant contributions in the field of pharmaceutical chemistry. With an impressive record of 27 patents, he has been instrumental in developing innovative compounds that offer potential therapeutic benefits.

Latest Patents

Among his latest patents, Ranjit has introduced unique chemical compounds such as 2-Saccharinylmethyl heterocyclic carboxylates that are useful as proteolytic enzyme inhibitors. These compounds are synthesized through the reaction of halomethylsaccharin with heterocyclic carboxylic acids in specific conditions. His work not only advances scientific understanding but also provides avenues for treating degenerative diseases.

Career Highlights

Ranjit has enjoyed a fruitful career, having worked with prominent companies such as Sterling Winthrop Inc. and Sanofi. His experience in these organizations has allowed him to develop and refine his innovative ideas, ultimately leading to his numerous patent filings.

Collaborations

Throughout his career, Ranjit has collaborated with talented professionals, including Dennis J Hlasta and Richard P Dunlap. These partnerships have proven valuable in enhancing his research efforts and expanding the scope of his inventions.

Conclusion

Ranjit C Desai stands out as a leading figure in pharmaceutical innovation. His dedication to research and development has resulted in a remarkable portfolio of patents that promise to impact the treatment of various diseases. As he continues to work in this challenging field, his contributions will undoubtedly inspire future breakthroughs.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]